Development of therapeutic HPV vaccines

Cornelia L Trimble, Ian H. Frazer

Research output: Contribution to journalArticle

Abstract

At least 15% of human malignant diseases are attributable to the consequences of persistent viral or bacterial infection. Chronic infection with oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the development of more cancers than any other virus. Currently available prophylactic vaccines have no therapeutic effect for established infection or for disease. Early disease is characterised by tissue sequestration. However, because a proportion of intraepithelial HPV-associated disease undergoes immune-mediated regression, the development of immunotherapeutic strategies is an opportunity to determine proof-of-principle for therapeutic vaccines. In this Review, we discuss recent progress in this field and priorities for future clinical investigations.

Original languageEnglish (US)
Pages (from-to)975-980
Number of pages6
JournalThe Lancet Oncology
Volume10
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Papillomavirus Vaccines
Vaccines
Immune System Diseases
Therapeutic Uses
Virus Diseases
Infection
Bacterial Infections
Therapeutics
Viruses
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Development of therapeutic HPV vaccines. / Trimble, Cornelia L; Frazer, Ian H.

In: The Lancet Oncology, Vol. 10, No. 10, 10.2009, p. 975-980.

Research output: Contribution to journalArticle

Trimble, Cornelia L ; Frazer, Ian H. / Development of therapeutic HPV vaccines. In: The Lancet Oncology. 2009 ; Vol. 10, No. 10. pp. 975-980.
@article{e2264c8a0bc4471d9a01ed10754c8bde,
title = "Development of therapeutic HPV vaccines",
abstract = "At least 15{\%} of human malignant diseases are attributable to the consequences of persistent viral or bacterial infection. Chronic infection with oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the development of more cancers than any other virus. Currently available prophylactic vaccines have no therapeutic effect for established infection or for disease. Early disease is characterised by tissue sequestration. However, because a proportion of intraepithelial HPV-associated disease undergoes immune-mediated regression, the development of immunotherapeutic strategies is an opportunity to determine proof-of-principle for therapeutic vaccines. In this Review, we discuss recent progress in this field and priorities for future clinical investigations.",
author = "Trimble, {Cornelia L} and Frazer, {Ian H.}",
year = "2009",
month = "10",
doi = "10.1016/S1470-2045(09)70227-X",
language = "English (US)",
volume = "10",
pages = "975--980",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Development of therapeutic HPV vaccines

AU - Trimble, Cornelia L

AU - Frazer, Ian H.

PY - 2009/10

Y1 - 2009/10

N2 - At least 15% of human malignant diseases are attributable to the consequences of persistent viral or bacterial infection. Chronic infection with oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the development of more cancers than any other virus. Currently available prophylactic vaccines have no therapeutic effect for established infection or for disease. Early disease is characterised by tissue sequestration. However, because a proportion of intraepithelial HPV-associated disease undergoes immune-mediated regression, the development of immunotherapeutic strategies is an opportunity to determine proof-of-principle for therapeutic vaccines. In this Review, we discuss recent progress in this field and priorities for future clinical investigations.

AB - At least 15% of human malignant diseases are attributable to the consequences of persistent viral or bacterial infection. Chronic infection with oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the development of more cancers than any other virus. Currently available prophylactic vaccines have no therapeutic effect for established infection or for disease. Early disease is characterised by tissue sequestration. However, because a proportion of intraepithelial HPV-associated disease undergoes immune-mediated regression, the development of immunotherapeutic strategies is an opportunity to determine proof-of-principle for therapeutic vaccines. In this Review, we discuss recent progress in this field and priorities for future clinical investigations.

UR - http://www.scopus.com/inward/record.url?scp=70349456743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349456743&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(09)70227-X

DO - 10.1016/S1470-2045(09)70227-X

M3 - Article

C2 - 19796749

AN - SCOPUS:70349456743

VL - 10

SP - 975

EP - 980

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -